MetaCap

Solventum (SOLV) vs Stryker (SYK)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Solventum (SOLV) has outperformed Stryker (SYK) over the past year, gaining 1.9% versus a loss of 15.8%. Stryker is the larger company by market cap ($118.01 billion vs $14.36 billion), about 8.2 times the size. On valuation, Solventum trades at a lower forward P/E (11.2x vs 19.0x for Stryker).

Stryker pays a dividend yielding 1.14%, while Solventum does not currently pay one. Solventum converts more of its revenue into profit, with a net margin of 18.7% versus 12.9%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

SOLV+1.93%SYK-15.82%
+13%-8%-29%
Nov 21, 20251 yearNov 20, 2026
SOLV+21.50%SYK-13.38%
+35%+1%-33%
Mar 25, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

SOLV versus SYK key metrics
MetricSOLVSYK
Share price$84.50$310.00
Market cap$14.36B$118.01B
1-day change-1.52%-0.98%
YTD return+6.64%-11.80%
1-year return+1.93%-15.82%
5-year return—+27.32%
P/E ratio (TTM)94.9433.01
Forward P/E11.2019.03
EPS (TTM)$0.89$9.39
Dividend yield0.00%1.14%
Annual dividend$0.00$3.52
Revenue (latest FY)$8.32B$25.12B
Revenue growth (YoY)+0.86%+11.16%
Net income (latest FY)$1.56B$3.25B
Gross margin53.47%63.96%
Operating margin26.20%19.47%
Net margin18.69%12.92%
52-week high$94.16$389.33
52-week low$62.38$267.00
Distance from 52-week high-10.26%-20.38%
Analyst consensusbuybuy
Avg. price target upside+16.43%+9.47%
Average volume1.03M2.93M
Shares outstanding169.96M380.69M
Employees20,58456,000
SectorHealth CareHealth Care
IndustryMedical/Dental InstrumentsMedical/Dental Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Stryker is about 8.2 times larger than Solventum by market value ($118.01B vs $14.36B).
  • SOLV has outperformed SYK by 17.8 percentage points over the past year.
  • Solventum trades at a higher earnings multiple (94.9x vs 33.0x trailing P/E).
  • Stryker offers a meaningfully higher dividend yield (1.14% vs 0.00%).
  • Solventum is more profitable, keeping 18.7 cents of every revenue dollar as net income versus 12.9 cents for Stryker.
  • Stryker grew revenue faster in its latest fiscal year (+11.16% vs +0.86%).

About Solventum

SOLV stock →

Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. It operates through three segments: Medsurg, Dental Solutions, and Health Information Systems.

Health Care · Medical/Dental Instruments · 20,584 employees

About Stryker

SYK stock →

Stryker Corporation operates as a medical technology company in the United States and internationally. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics.

Health Care · Medical/Dental Instruments · 56,000 employees

SOLV vs SYK FAQ

Which is bigger, Solventum or Stryker?

Stryker (SYK) is larger, with a market capitalization of $118.01B compared with $14.36B for Solventum (SOLV).

Which stock has performed better over the past year, SOLV or SYK?

SOLV returned +1.93% over the past 12 months, compared with -15.82% for SYK (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, SOLV or SYK?

SYK has the lower trailing P/E at 33.0, versus 94.9 for SOLV. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Which pays a higher dividend, Solventum or Stryker?

Stryker pays a dividend yielding 1.14%, while Solventum does not currently pay a regular dividend.

Are Solventum and Stryker in the same industry?

Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.

More comparisons